Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Zugman

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Oncologist|June 29, 2026
Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 FrameworkMiguel Zugman, Pedro C Barata
European Urology|January 18, 2025
Pembrolizumab Retreatment: Lessons from a Selected Group of Patients with Urothelial CarcinomaMiguel Zugman, Charles B Nguyen
Cancers|December 23, 2023
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future DirectionsBeatriz Bertin, Miguel Zugman, Gustavo Schvartsman
Journal of Cancer Policy|April 8, 2024
INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomasMiguel Zugman, Alyson Haslam, Vinay Prasad
JCO Precision Oncology|November 20, 2024
New Molecular Targets in Prostate Cancer-The Emerging Role of <i>ACP1</i> and Low Molecular Weight Protein Tyrosine PhosphataseMiguel Zugman, Alexander Chehrazi-Raffle, Oren Smaletz
European Urology|September 18, 2025
Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder CancerMiguel Zugman, Ariê Carneiro, Fernando C Maluf
Urologic Oncology|August 2, 2024
The gut microbiome and dietary metabolites in the treatment of renal cell carcinomaMiguel Zugman, Megan Wong, Salvador Jaime-Casas, et al.
Frontiers in Oncology|May 16, 2022
Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural MesotheliomaFrancinne T Tostes, Miguel Zugman, Vitor R Paes, et al.
European Urology Focus|January 31, 2025
What Is the Role of Fecal Microbiota Transplantation in Immunotherapy Trials? Current Perspectives and Future DirectionsEdmond Rafie, Miguel Zugman, Sumanta K Pal, et al.
Frontiers in Oncology|April 21, 2022
Precision Medicine Targeting <i>FGFR2</i> Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future PerspectivesMiguel Zugman, Gehan Botrus, Roberto Carmagnani Pestana, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Oncologist|June 29, 2026
Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 FrameworkMiguel Zugman, Pedro C Barata
European Urology|January 18, 2025
Pembrolizumab Retreatment: Lessons from a Selected Group of Patients with Urothelial CarcinomaMiguel Zugman, Charles B Nguyen
Cancers|December 23, 2023
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future DirectionsBeatriz Bertin, Miguel Zugman, Gustavo Schvartsman
Journal of Cancer Policy|April 8, 2024
INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomasMiguel Zugman, Alyson Haslam, Vinay Prasad
JCO Precision Oncology|November 20, 2024
New Molecular Targets in Prostate Cancer-The Emerging Role of <i>ACP1</i> and Low Molecular Weight Protein Tyrosine PhosphataseMiguel Zugman, Alexander Chehrazi-Raffle, Oren Smaletz
European Urology|September 18, 2025
Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder CancerMiguel Zugman, Ariê Carneiro, Fernando C Maluf
Urologic Oncology|August 2, 2024
The gut microbiome and dietary metabolites in the treatment of renal cell carcinomaMiguel Zugman, Megan Wong, Salvador Jaime-Casas, et al.
Frontiers in Oncology|May 16, 2022
Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural MesotheliomaFrancinne T Tostes, Miguel Zugman, Vitor R Paes, et al.
European Urology Focus|January 31, 2025
What Is the Role of Fecal Microbiota Transplantation in Immunotherapy Trials? Current Perspectives and Future DirectionsEdmond Rafie, Miguel Zugman, Sumanta K Pal, et al.
Frontiers in Oncology|April 21, 2022
Precision Medicine Targeting <i>FGFR2</i> Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future PerspectivesMiguel Zugman, Gehan Botrus, Roberto Carmagnani Pestana, et al.
Pageof 3